These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 15993811)

  • 1. Dopamine D3 receptor antagonists as therapeutic agents.
    Joyce JN; Millan MJ
    Drug Discov Today; 2005 Jul; 10(13):917-25. PubMed ID: 15993811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo occupancy of dopamine D3 receptors by antagonists produces neurochemical and behavioral effects of potential relevance to attention-deficit-hyperactivity disorder.
    Barth V; Need AB; Tzavara ET; Giros B; Overshiner C; Gleason SD; Wade M; Johansson AM; Perry K; Nomikos GG; Witkin JM
    J Pharmacol Exp Ther; 2013 Feb; 344(2):501-10. PubMed ID: 23197772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of dopamine D(3) receptors in antipsychotic activity and cognitive functions.
    Gross G; Drescher K
    Handb Exp Pharmacol; 2012; (213):167-210. PubMed ID: 23027416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopamine D3 and D4 receptor antagonists in the treatment of schizophrenia.
    Jardemark K; Wadenberg ML; Grillner P; Svensson TH
    Curr Opin Investig Drugs; 2002 Jan; 3(1):101-5. PubMed ID: 12054059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopamine D3 receptor partial agonists and antagonists as potential drug abuse therapeutic agents.
    Newman AH; Grundt P; Nader MA
    J Med Chem; 2005 Jun; 48(11):3663-79. PubMed ID: 15916415
    [No Abstract]   [Full Text] [Related]  

  • 6. Synthesis and SAR of highly potent and selective dopamine D3-receptor antagonists: variations on the 1H-pyrimidin-2-one theme.
    Geneste H; Amberg W; Backfisch G; Beyerbach A; Braje WM; Delzer J; Haupt A; Hutchins CW; King LL; Sauer DR; Unger L; Wernet W
    Bioorg Med Chem Lett; 2006 Apr; 16(7):1934-7. PubMed ID: 16439127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-fused and hetero-fused systems.
    Micheli F; Bonanomi G; Braggio S; Capelli AM; Damiani F; Di Fabio R; Donati D; Gentile G; Hamprecht D; Perini O; Petrone M; Tedesco G; Terreni S; Worby A; Heidbreder C
    Bioorg Med Chem Lett; 2008 Feb; 18(3):908-12. PubMed ID: 18178090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent. II. A neurochemical, electrophysiological and behavioral characterization in vivo.
    Millan MJ; Svenningsson P; Ashby CR; Hill M; Egeland M; Dekeyne A; Brocco M; Di Cara B; Lejeune F; Thomasson N; Munoz C; Mocaër E; Crossman A; Cistarelli L; Girardon S; Iob L; Veiga S; Gobert A
    J Pharmacol Exp Ther; 2008 Feb; 324(2):600-11. PubMed ID: 18024787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blonanserin, an antipsychotic and dopamine D₂/D₃receptor antagonist, and ameliorated alcohol dependence.
    Takaki M; Ujike H
    Clin Neuropharmacol; 2013; 36(2):68-9. PubMed ID: 23503552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective dopamine D3 receptor antagonists: a review 2001-2005.
    Micheli F; Heidbreder C
    Recent Pat CNS Drug Discov; 2006 Nov; 1(3):271-88. PubMed ID: 18221209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances in the development of dopamine D3 receptor antagonists: a medicinal chemistry perspective.
    Micheli F
    ChemMedChem; 2011 Jul; 6(7):1152-62. PubMed ID: 21425240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.
    Micheli F; Bonanomi G; Braggio S; Capelli AM; Celestini P; Damiani F; Di Fabio R; Donati D; Gagliardi S; Gentile G; Hamprecht D; Petrone M; Radaelli S; Tedesco G; Terreni S; Worby A; Heidbreder C
    Bioorg Med Chem Lett; 2008 Feb; 18(3):901-7. PubMed ID: 18248991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blockade of dopamine D(3) receptors in frontal cortex, but not in sub-cortical structures, enhances social recognition in rats: similar actions of D(1) receptor agonists, but not of D(2) antagonists.
    Loiseau F; Millan MJ
    Eur Neuropsychopharmacol; 2009 Jan; 19(1):23-33. PubMed ID: 18793829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cognitive impairment in schizophrenia: a review of developmental and genetic models, and pro-cognitive profile of the optimised D(3) > D(2) antagonist, S33138.
    Millan MJ; Brocco M
    Therapie; 2008; 63(3):187-229. PubMed ID: 18718210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methamphetamine-induced locomotor activity and behavioral sensitization: are dopamine d3 receptors involved?
    Jones CD; Bartee JA; Leite-Browning ML; Blackshear MA
    Cell Mol Biol (Noisy-le-grand); 2007 May; 53(4):15-22. PubMed ID: 17531156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. S33138 (N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1] benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenyl-acetamide), a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: III. Actions in models of therapeutic activity and induction of side effects.
    Millan MJ; Loiseau F; Dekeyne A; Gobert A; Flik G; Cremers TI; Rivet JM; Sicard D; Billiras R; Brocco M
    J Pharmacol Exp Ther; 2008 Mar; 324(3):1212-26. PubMed ID: 18096759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KKHA-761, a potent D3 receptor antagonist with high 5-HT1A receptor affinity, exhibits antipsychotic properties in animal models of schizophrenia.
    Park WK; Jeong D; Cho H; Lee SJ; Cha MY; Pae AN; Choi KI; Koh HY; Kong JY
    Pharmacol Biochem Behav; 2005 Oct; 82(2):361-72. PubMed ID: 16216322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopamine D3 receptor antagonists: a patent review (2007 - 2012).
    Micheli F; Heidbreder C
    Expert Opin Ther Pat; 2013 Mar; 23(3):363-81. PubMed ID: 23282131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serotonin and dopamine interactions in psychosis prevention.
    Richtand NM; McNamara RK
    Prog Brain Res; 2008; 172():141-53. PubMed ID: 18772031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current perspectives on selective dopamine D(3) receptor antagonists as pharmacotherapeutics for addictions and related disorders.
    Heidbreder CA; Newman AH
    Ann N Y Acad Sci; 2010 Feb; 1187():4-34. PubMed ID: 20201845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.